Literature DB >> 17239630

Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing.

David J J de Gorter1, Esther A Beuling, Rogier Kersseboom, Sabine Middendorp, Janine M van Gils, Rudolf W Hendriks, Steven T Pals, Marcel Spaargaren.   

Abstract

Control of integrin-mediated adhesion and migration by chemokines plays a critical role in B cell development, differentiation, and function; however, the underlying signaling mechanisms are poorly defined. Here we show that the chemokine SDF-1 induced activation of Bruton's tyrosine kinase (Btk) and that integrin-mediated adhesion and migration in response to SDF-1 or CXCL13, as well as in vivo homing to lymphoid organs, was impaired in Btk-deficient (pre-)B cells. Furthermore, SDF-1 induced tyrosine phosphorylation of Phospholipase Cgamma2 (PLCgamma2), which, unlike activation of the migration regulatory GTPases Rac or Rap1, was mediated by Btk. PLCgamma2-deficient B cells also exhibited impaired SDF-1-controlled migration. These results reveal that Btk and PLCgamma2 mediate chemokine-controlled migration, thereby providing insights into the control of B cell homeostasis, trafficking, and function, as well as into the pathogenesis of the immunodeficiency disease X-linked agammaglobulinemia (XLA).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17239630     DOI: 10.1016/j.immuni.2006.11.012

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  114 in total

Review 1.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

2.  Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

Authors:  Andrew J Gunderson; Megan M Kaneda; Takahiro Tsujikawa; Abraham V Nguyen; Nesrine I Affara; Brian Ruffell; Sara Gorjestani; Shannon M Liudahl; Morgan Truitt; Peter Olson; Grace Kim; Douglas Hanahan; Margaret A Tempero; Brett Sheppard; Bryan Irving; Betty Y Chang; Judith A Varner; Lisa M Coussens
Journal:  Cancer Discov       Date:  2015-12-29       Impact factor: 39.397

Review 3.  Bruton Tyrosine Kinase Inhibitors: Present and Future.

Authors:  Jan A Burger
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

4.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

Review 5.  Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2017-11-28

Review 6.  Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase.

Authors:  J S Oak; M P Matheu; I Parker; M D Cahalan; D A Fruman
Journal:  Biochem Soc Trans       Date:  2007-11       Impact factor: 5.407

7.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 8.  Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk.

Authors:  Julie A Readinger; Kristen L Mueller; Ana M Venegas; Reiko Horai; Pamela L Schwartzberg
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

9.  Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Authors:  Rakesh Bam; Wen Ling; Sharmin Khan; Angela Pennisi; Sathisha Upparahalli Venkateshaiah; Xin Li; Frits van Rhee; Saad Usmani; Bart Barlogie; John Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2013-03-28       Impact factor: 10.047

10.  Cell Trafficking in Chronic Lymphocytic Leukemia.

Authors:  Matthew S Davids; Jan A Burger
Journal:  Open J Hematol       Date:  2012-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.